Ergosterol (Synonyms: Provitamin D2) |
Catalog No.GN10349
One-Click Copy Product Info
|
Ergosterol is a sterol unique to fungal cell membranes with antioxidant and antiproliferative activities.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 57-87-4
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Ergosterol is a sterol unique to fungal cell membranes with antioxidant and antiproliferative activities. Ergosterol activates mitochondrial ACSL1 to promote fatty acid β-oxidation, thereby alleviating fatty liver and insulin resistance, while reducing inflammation through inhibition of the NF-κB pathway. Ergosterol can be used in research related to metabolic diseases and antifungal drugs[1-4].
In vitro, Ergosterol (2.5–40μM) was applied to human breast cancer cells MCF-7 and MDA-MB-231 for 24–96h. Ergosterol inhibited cell viability, induced G0/G1 phase cell cycle arrest, suppressed spheroid formation, downregulated c-Myc and cyclin D1 expression, blocked β-catenin nuclear translocation, inhibited AKT and GSK-3β phosphorylation, promoted β-catenin degradation, suppressed protein synthesis, and downregulated USP47 and USP9x expression[5]. Ergosterol (0–300μM) was applied to MDA-MB-231, MDA-MB-468, SK-BR-3, MCF-7 human breast cancer cells and 4T1 mouse breast cancer cells for 24–48h. Ergosterol dose-dependently inhibited the viability, migration, and invasion of breast cancer cells, reduced colony number and size, induced apoptosis in MDA-MB-231 cells, and upregulated the mRNA and protein expression of Foxo3 and its downstream targets BimL, BimS, Fas, and FasL[6].
In vivo, Ergosterol (50mg/kg and 100mg/kg) was administered once daily by oral gavage to Streptozotocin (STZ)-induced diabetic nephropathy mice and normal mice for 5 weeks. Ergosterol reduced fasting blood glucose and blood lipids, elevated serum insulin levels and HOMA-β, alleviated kidney injury, and downregulated the mRNA and protein expression of IL-6, TNF-α, and MCP-1 in serum and renal tissue, while inhibiting p-NF-κB(p65), COX-2, and iNOS expression in renal tissue[7]. Ergosterol (0, 2, 7mg/kg) was incorporated into the diet and fed daily to wild-type C57BL/6NCrl male mice for 6 weeks. Ergosterol (7mg/kg) increased vitamin D3 levels in serum, liver, and kidney[8].
References:
[1] Yao M, Li C, Dang M, et al. Ergosterol: Biological Activities, Mechanistic Evidence, Pharmacokinetic Barriers, and Delivery Strategies. Int J Mol Sci. 2026 May 8;27(10):4198.
[2] Stefaniak-Skorupa J, Milewska MJ. Ergosterol and Lanosterol Derivatives: Synthesis and Possible Biomedical Applications. ChemMedChem. 2025 May 19;20(10):e202400948.
[3] Jordá T, Puig S. Regulation of Ergosterol Biosynthesis in Saccharomyces cerevisiae. Genes (Basel). 2020 Jul 15;11(7):795.
[4] Suárez Y, Fernández C, Ledo B, et al. Differential effects of ergosterol and cholesterol on Cdk1 activation and SRE-driven transcription. Eur J Biochem. 2002 Mar;269(6):1761-71.
[5] Li X, Wu Q, Xie Y, et al. Ergosterol purified from medicinal mushroom Amauroderma rude inhibits cancer growth in vitro and in vivo by up-regulating multiple tumor suppressors. Oncotarget. 2015 Jul 10;6(19):17832-46.
[6] Nilkhet S, Vongthip W, Lertpatipanpong P, et al. Ergosterol inhibits the proliferation of breast cancer cells by suppressing AKT/GSK-3beta/beta-catenin pathway. Sci Rep. 2024 Aug 24;14(1):19664.
[7] Liu C, Zhao S, Zhu C, et al. Ergosterol ameliorates renal inflammatory responses in mice model of diabetic nephropathy. Biomed Pharmacother. 2020 Aug;128:110252.
[8] Zheng ZG, Zhang YP, Zhang XY, et al. Ergosterol alleviates hepatic steatosis and insulin resistance via promoting fatty acid β-oxidation by activating mitochondrial ACSL1. Cell Rep. 2025 Jan 28;44(1):115203.
| Cell experiment [1]: | |
Cell lines | MCF-7 human breast cancer cells, MDA-MB-231 human triple-negative breast cancer cells |
Preparation Method | MCF-7 and MDA-MB-231 cells were maintained in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin and 1% sodium pyruvate at 37°C, 5% CO₂. Cells were treated with Ergosterol at concentrations of 2.5-40μM for 24, 48 or 96h. |
Reaction Conditions | 2.5-40μM; 24-96h |
Applications | Ergosterol inhibited the viability of both cell lines in a dose-dependent manner, with IC50 values of 6.70±1.51μM (MCF-7, 24h) and 15.55±6.84μM (MDA-MB-231, 48h). Ergosterol (20μM, 24h) induced G0/G1 phase cell cycle arrest and suppressed spheroid formation in the presence or absence of Matrigel. Ergosterol downregulated c-Myc and cyclin D1 expression, inhibited β-catenin nuclear translocation, suppressed AKT(S473) and GSK-3β phosphorylation to promote β-catenin degradation, reduced global protein synthesis via downregulating phosphorylated 4EBP1, and suppressed deubiquitinases USP47 and USP9x expression. Ergosterol ltered metabolic pathways in MDA-MB-231 cells including steroid hormone biosynthesis, nitrogen metabolism, sphingolipid metabolism, pyrimidine metabolism and glycosaminoglycan biosynthesis. |
| Animal experiment [2]: | |
Animal models | Streptozotocin (STZ)-induced diabetic nephropathy mice, with normal mice as negative control |
Preparation Method | Diabetic nephropathy model was established by intraperitoneal injection of STZ at 30mg/kg once a week for 3 weeks, mice with serum glucose of 11-18mM 5 days after the last STZ injection were enrolled as successful models. Enrolled model mice were randomized into model control (received vehicle), 50mg/kg Ergosterol group and 100mg/kg Ergosterol group, Ergosterol was administered via daily oral gavage for 5 weeks, normal control group received corresponding vehicle. |
Dosage form | 50mg/kg, 100mg/kg; oral gavage; once a day for 5 weeks |
Applications | Ergosterol treatment reduced fasting blood glucose, total cholesterol, triglyceride, low-density lipoprotein cholesterol levels, increased serum insulin, high-density lipoprotein cholesterol and HOMA-β levels in diabetic nephropathy mice. Ergosterol attenuated renal injury as evidenced by decreased blood urea nitrogen, serum creatinine, urinary albumin and albumin/creatinine ratio, and relieved renal mesangial proliferation. Ergosterol downregulated IL-6, TNF-α, MCP-1 mRNA and protein expressions in serum and renal tissues, and inhibited renal p-NF-κB(p65), COX-2, iNOS protein expressions. |
References: | |
| Cas No. | 57-87-4 | SDF | |
| Sinónimos | Provitamin D2 | ||
| Chemical Name | (3S,9S,10R,13R,14R,17R)-17-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-10,13-dimethyl-2,3,4,9,11,12,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-ol | ||
| Canonical SMILES | CC(C)C(C)C=CC(C)C1CCC2C1(CCC3C2=CC=C4C3(CCC(C4)O)C)C | ||
| Formula | C28H44O | M.Wt | 396.66 |
| Solubility | <2.95mg/mL in DMSO | Storage | 4°C, protect from light |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.5211 mL | 12.6053 mL | 25.2105 mL |
| 5 mM | 504.2 μL | 2.5211 mL | 5.0421 mL |
| 10 mM | 252.1 μL | 1.2605 mL | 2.5211 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)